Scholarlink

Background <p>Sarcopenia, the age-related loss of muscle mass and strength, is a leading cause of disability and frailty in older adults. Though primarily seen as a musculoskeletal condition, emerging evidence suggests a role for neurodegenerative mechanisms such as axonal loss and neuroinflammation. Circulating biomarkers like glial fibrillary acidic protein (GFAP), reflecting astrocyte activation, and neurofilament light chain (NfL), indicating axonal injury, may signal subclinical neurological dysfunction. This study examined associations between plasma GFAP and NfL levels and the presence and severity of sarcopenia in older Indian adults using data from the nationally representative Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD) cohort.</p> Methods <p>We used data from the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD), a nationally representative sample of older adults aged ≥ 60 years. Sarcopenia was classified using Asian Working Group for Sarcopenia (AWGS) 2019 criteria based on handgrip strength, gait speed, and calf circumference, and categorized into no sarcopenia, sarcopenia, and severe sarcopenia. Plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using Simoa<sup>®</sup> HDX platform.</p> Results <p>We analyzed 1,429 community-dwelling older adults; 53.1% had sarcopenia and 38.6% had severe sarcopenia. Median plasma GFAP levels increased from 99.6 pg/mL (IQR: 70.2–140.9) in those without sarcopenia to 122.4 pg/mL (IQR: 84.0–181.6) in sarcopenia and 158.1 pg/mL (IQR: 101.4–228.4) in severe sarcopenia (<i>p</i> &lt; 0.001). Similarly, median NfL levels were 20.5 pg/mL (IQR: 15.8–29.4), 29.1 pg/mL (IQR: 19.8–44.6), and 37.6 pg/mL (IQR: 25.0–59.2), respectively (<i>p</i> &lt; 0.001). In fully adjusted models, higher GFAP levels were associated with sarcopenia (RRR: 1.23; 95% CI: 1.04–1.45; <i>p</i> = 0.014) and severe sarcopenia (RRR: 1.48; 95% CI: 1.19–1.83; <i>p</i> &lt; 0.001). NfL was associated with sarcopenia (RRR: 1.37; 95% CI: 1.16–1.61; <i>p</i> &lt; 0.001) and severe sarcopenia (RRR: 2.01; 95% CI: 1.56–2.58; <i>p</i> &lt; 0.001).</p> Conclusion <p>Elevated GFAP and NfL were independently associated with greater sarcopenia severity, suggesting neurodegenerative involvement in sarcopenia among older Indian adults. These biomarkers may offer valuable insights into the neural contributions to muscle decline in aging populations and could support future risk stratification and early intervention strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between neurofilament light chain, glial fibrillary acidic protein, and sarcopenia in older Indian adults: evidence from LASI-DAD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月11日

查看全文
  • Abhijith Rajaram Rao,
  • Manjusha Bhagwasia,
  • Masroor Anwar,
  • Akshata Rao,
  • Avinash Chakrawarty,
  • Aparajit Ballav Dey,
  • Sharmistha Dey

摘要

Background

Sarcopenia, the age-related loss of muscle mass and strength, is a leading cause of disability and frailty in older adults. Though primarily seen as a musculoskeletal condition, emerging evidence suggests a role for neurodegenerative mechanisms such as axonal loss and neuroinflammation. Circulating biomarkers like glial fibrillary acidic protein (GFAP), reflecting astrocyte activation, and neurofilament light chain (NfL), indicating axonal injury, may signal subclinical neurological dysfunction. This study examined associations between plasma GFAP and NfL levels and the presence and severity of sarcopenia in older Indian adults using data from the nationally representative Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD) cohort.

Methods

We used data from the Longitudinal Aging Study in India–Diagnostic Assessment of Dementia (LASI-DAD), a nationally representative sample of older adults aged ≥ 60 years. Sarcopenia was classified using Asian Working Group for Sarcopenia (AWGS) 2019 criteria based on handgrip strength, gait speed, and calf circumference, and categorized into no sarcopenia, sarcopenia, and severe sarcopenia. Plasma levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) were quantified using Simoa® HDX platform.

Results

We analyzed 1,429 community-dwelling older adults; 53.1% had sarcopenia and 38.6% had severe sarcopenia. Median plasma GFAP levels increased from 99.6 pg/mL (IQR: 70.2–140.9) in those without sarcopenia to 122.4 pg/mL (IQR: 84.0–181.6) in sarcopenia and 158.1 pg/mL (IQR: 101.4–228.4) in severe sarcopenia (p < 0.001). Similarly, median NfL levels were 20.5 pg/mL (IQR: 15.8–29.4), 29.1 pg/mL (IQR: 19.8–44.6), and 37.6 pg/mL (IQR: 25.0–59.2), respectively (p < 0.001). In fully adjusted models, higher GFAP levels were associated with sarcopenia (RRR: 1.23; 95% CI: 1.04–1.45; p = 0.014) and severe sarcopenia (RRR: 1.48; 95% CI: 1.19–1.83; p < 0.001). NfL was associated with sarcopenia (RRR: 1.37; 95% CI: 1.16–1.61; p < 0.001) and severe sarcopenia (RRR: 2.01; 95% CI: 1.56–2.58; p < 0.001).

Conclusion

Elevated GFAP and NfL were independently associated with greater sarcopenia severity, suggesting neurodegenerative involvement in sarcopenia among older Indian adults. These biomarkers may offer valuable insights into the neural contributions to muscle decline in aging populations and could support future risk stratification and early intervention strategies.